PLRZHealthcare · BiotechnologyTicker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 15 of 100 as at 27 Oct 2026 — in the weakest quartile.
Consensus tells you what everyone already believes. The model scores Polyrizon Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (87): Smaller than most of the companies we track.
Value (7): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on PLRZ, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
PLRZ appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 28 Oct 2026, Polyrizon Ltd. returned +1.5% against +13.6% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 77% of US stocks
Cheaper than 65% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 31% of US stocks
Higher than 17% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Polyrizon Ltd. has a market value of $20.8M and an enterprise value of $2.2M.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Polyrizon Ltd. employs 2 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Polyrizon Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Polyrizon announced that all 120 planned participants were enrolled and randomized across five U.S. clinical sites in its study of NASARIX, an investigational nasal hydrogel designed to protect against airborne allergens.
Why it matters — Completion of enrollment marks a study milestone for PLRZ’s NASARIX candidate.
Polyrizon has filed a new U.S. patent application covering its proprietary mucoadhesive platform and its potential applications in intranasal drug delivery. The filing is intended to expand the company's intellectual property moat around its drug-delivery technology.
Why it matters — PLRZ watchers would care because a broader patent portfolio could strengthen the company's competitive position and protections for its intranasal drug-delivery platform.
Polyrizon has enrolled its first patient in a U.S. clinical study of its NASARIX (PL-14) Allergy Blocker, which is designed to evaluate the efficacy, safety and tolerability of the product in patients with seasonal allergic rhinitis. This marks the company's transition into a clinical-stage company.
Why it matters — A PLRZ watcher would care because this milestone advances the company from a pre-clinical to a clinical-stage developer, moving its lead allergy product closer to potential regulatory validation.
Polyrizon Ltd. announced the closing of a $4.0 million registered direct offering and private placement. The company, headquartered in Raanana, Israel, made the announcement on September 4, 2026.
Why it matters — The closing of this offering indicates the company has secured new capital, which PLRZ watchers would track as a liquidity and financing event.
Polyrizon Ltd. announced it has entered into definitive agreements with a single institutional investor for a registered direct offering of its Ordinary Shares and pre-funded warrants, along with a concurrent private placement of pre-funded and investor warrants. Aggregate gross proceeds from both transactions are expected to be approximately $4.0 million.
Why it matters — This capital raise provides Polyrizon with funding for its development-stage intranasal hydrogel programs.
As at 27 Oct 2026, Polyrizon Ltd. ranks 15 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (87 of 100).
No analyst covering Polyrizon Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PLRZ are extrapolating price history, which says nothing about the business.
Polyrizon Ltd. returned +1.5% over the 12 months to 28 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Polyrizon Ltd. is an Israel-based biotechnology company focused on developing innovative intranasal protective products.
The most recent item we track (GlobeNewsWire, 27 Oct 2026): "Polyrizon Announces Successful Completion Enrollment of all 120 Patients in U.S. Clinical Study of NASARIX Allergy Blocker". Polyrizon announced that all 120 planned participants were enrolled and randomized across five U.S. clinical sites in its study of NASARIX, an investigational nasal hydrogel designed to protect against airborne allergens.
Polyrizon Ltd. is an Israel-based biotechnology company focused on developing innovative intranasal protective products. The company specializes in medical device hydrogels delivered as nasal sprays that form a thin barrier in the nasal cavity, designed to help prevent viruses, allergens, and other airborne particles from contacting nasal tissue. Its proprietary Capture and Contain technology is intended to create a temporary shield in the nose, while its Trap and Target platform supports intranasal delivery of active pharmaceutical ingredients. Polyrizon also develops product candidates aimed at nasal allergy blocking and influenza protection. In addition to preventative intranasal solutions, the company works on improving bioadhesion and retention characteristics for drug delivery applications. Polyrizon Ltd. serves the healthcare and biotechnology markets through research, development, and commercialization of nasal-care technologies.
CEO Mr. Tomer Izraeli · 2 employees · Israel · https://www.polyrizon-biotech.com
